The South America insulin pens market size is expected to grow from USD 0.83 billion in 2025 to USD 0.88 billion in 2026 and is forecast to reach USD 1.15 billion by 2031 at 5.51% CAGR over 2026-2031. This report is segmented by Product Type (Disposable Insulin Pens, Cartridges in Reusable Insulin Pens, and More), Diabetes Type (Type 1, Type 2, and More), End User (Home and Self-Administration, Hospitals and More), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and More), and Geography (Brazil, Argentina, and More). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Disposable insulin pens remain relevant in private care and at clinical initiation; their higher cost per use limits wider uptake where public systems control most dispensing volumes. Smart and connected insulin pens are projected to grow at a 9.58% CAGR through 2031. Urban private networks in Brazil are early channels for connected delivery tools. Modular Bluetooth caps can be fitted to reusable pens that patients already use. The clinical support for dose tracking strengthens the rationale for providers to adopt these tools.
Type 2 diabetes held 86.24% of the South America insulin pens market size in 2025. Most insulin-treated people in the region have a type 2 diagnosis. This creates a larger volume base than in markets where type 1 diabetes has historically led to premium pen adoption. Basal insulin initiation is important for patients whose glucose levels remain uncontrolled. Glargine cartridges and compatible reusable pens fit this pattern of treatment. The expected expansion of diabetes in South and Central America will largely add to the type 2 treatment population.
Type 1 diabetes has a smaller revenue position but remains important for device use. People with type 1 diabetes generally need multiple daily injections. That need can create higher per-patient use of pens, cartridges, and needles. Brazil's 2026 glargine pilot prioritized children and adolescents aged 2 to 17 with type 1 diabetes. It also included adults aged 80 and older with type 1 diabetes. Gestational and other diabetes is the smallest category, even though 1 in 6 live births in the region were affected by hyperglycemia in pregnancy in 2024.
South America Insulin Pens Market Trends and Insights
Rising Diabetes Burden and Insulin-Treated Population
The South America insulin pens market is linked to a diabetes burden that is expected to expand across the region. The adult diabetes population in South and Central America is projected to increase 46% to 52 million by 2050. The 30.4% undiagnosed share recorded in 2024 represented more than 10.7 million people who may enter treatment after screening improves. Brazil's Ministry of Health distributed 59 million units of NPH insulin and 12 million units of regular insulin through SUS in 2024. As glargine cartridges replace some NPH vials, reusable pen use can rise per treated patient without requiring a comparable rise in patient numbers.Shift From Syringes to Patient-Friendly Pen Administration
The South America insulin pens market is also shaped by the move away from syringe-and-vial therapy in major urban care settings. Pen systems can simplify dose administration for patients who receive education through public health units. The American Diabetes Association issued a Grade B recommendation in 2025 to offer connected insulin pens to people using multiple daily injections. This guidance can influence prescribing discussions within diabetes societies in Brazil and Argentina. Cost-sensitive public systems still favor reusable devices because cartridge refills can lower the cost of ongoing administration. Suppliers with cartridge and reusable pen platforms are therefore better placed than suppliers focused only on disposable formats.Uneven Reimbursement and High Out-of-Pocket Spending
The South America insulin pens market has uneven access beyond Brazil and Argentina. Brazil's SUS and Argentina's mandatory coverage framework support access for many patients. Other countries have narrower reimbursement arrangements for pen cartridges and needles. These gaps can make pens less affordable for patients who pay directly. The result is a concentration of revenue in the countries with stronger coverage, while other countries retain unmet treatment demand. Broader insurance coverage and a reliable supply would be necessary for this demand to become active device use.Other drivers and restraints analyzed in the detailed report include:
- Expansion of Public Diabetes Programs and Pen Access
- Growth of Connected Diabetes Management Ecosystems
- Currency Volatility and Import Dependence
Segment Analysis
Cartridges in reusable insulin pens accounted for 53.31% of the South America insulin pens market size in 2025. Their position reflects how public procurement programs evaluate the ongoing cost of insulin administration. SUS in Brazil favors compatible cartridge systems within its public dispensing structure. Argentina's reimbursement framework also supports the continued use of pen injectors for covered patients. Refillable formats can lower recurring treatment costs compared with single-use devices. This makes reusable products more suitable for systems that serve large numbers of patients over long periods.Disposable insulin pens remain relevant in private care and at clinical initiation; their higher cost per use limits wider uptake where public systems control most dispensing volumes. Smart and connected insulin pens are projected to grow at a 9.58% CAGR through 2031. Urban private networks in Brazil are early channels for connected delivery tools. Modular Bluetooth caps can be fitted to reusable pens that patients already use. The clinical support for dose tracking strengthens the rationale for providers to adopt these tools.
Type 2 diabetes held 86.24% of the South America insulin pens market size in 2025. Most insulin-treated people in the region have a type 2 diagnosis. This creates a larger volume base than in markets where type 1 diabetes has historically led to premium pen adoption. Basal insulin initiation is important for patients whose glucose levels remain uncontrolled. Glargine cartridges and compatible reusable pens fit this pattern of treatment. The expected expansion of diabetes in South and Central America will largely add to the type 2 treatment population.
Type 1 diabetes has a smaller revenue position but remains important for device use. People with type 1 diabetes generally need multiple daily injections. That need can create higher per-patient use of pens, cartridges, and needles. Brazil's 2026 glargine pilot prioritized children and adolescents aged 2 to 17 with type 1 diabetes. It also included adults aged 80 and older with type 1 diabetes. Gestational and other diabetes is the smallest category, even though 1 in 6 live births in the region were affected by hyperglycemia in pregnancy in 2024.
Complete Report Scope:
- By Product Type
- Disposable Insulin Pens
- Cartridges in Reusable Insulin Pens
- Smart and Connected Insulin Pens
- By Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational and Other Diabetes
- By End User
- Home and Self-Administration
- Hospitals and Clinics
- Ambulatory Care
- Other End Users
- By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies and E-Commerce
- Other Distribution Channels
- By Country
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
List of Companies Covered in this Report:
- B. Braun
- Beckton Dickinson
- Biocon
- Biomm S.A.
- Eli Lilly and Company
- embecta Corp.
- Fundação Oswaldo Cruz
- Gan & Lee Pharmaceuticals Group Co., Ltd.
- HTL-Strefa S.A.
- Julphar
- Lupin
- Medtronic
- Novo Nordisk
- Owen Mumford Limited
- Roche
- Sanofi
- Sun Pharmaceuticals Industries
- Terumo
- Wockhardt Limited
- Ypsomed
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities and Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- B. Braun SE
- Becton, Dickinson and Company
- Biocon Limited
- Biomm S.A.
- Eli Lilly and Company
- embecta Corp.
- Fundação Oswaldo Cruz
- Gan & Lee Pharmaceuticals Group Co., Ltd.
- HTL-Strefa S.A.
- Julphar
- Lupin Limited
- Medtronic plc
- Novo Nordisk A/S
- Owen Mumford Limited
- Roche Diabetes Care
- Sanofi
- Sun Pharmaceutical Industries Limited
- Terumo Corporation
- Wockhardt Limited
- Ypsomed Holding AG
